SML2292

CCG-100602

≥98% (HPLC)

• Synonim(y): 1-[3,5-Bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)-3-piperidinecarboxamide, 1-[3,5-Bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)piperidine-3-carboxamide, CCG 100602, CCG100602
• Wzór empiryczny (zapis Hilla): C₂₁H₁₇ClF₆N₂O₂
• Numer CAS: 1207113-88-9
• Masa cząsteczkowa: 478.82
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: −20°C
• SMILES string: O=C(N1CCCC(C(NC2=CC=C(Cl)C=C2)=O)C1)C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3
• InChI: 1S/C21H17ClF6N2O2/c22-16-3-5-17(6-4-16)29-18(31)12-2-1-7-30(11-12)19(32)13-8-14(20(23,24)25)10-15(9-13)21(26,27)28/h3-6,8-10,12H,1-2,7,11H2,(H,29,31)
• InChI key: MOQCFMZWVKQBAP-UHFFFAOYSA-N

Opis

Biochem/physiol Actions

CCG-100602 aids in preventing fibrosis around the temporomandibular joint (TMJ).[1]

CCG-100602 is a CCG-1423 analog with significantly less cytotoxicity (0/14% WST-1 inhibition by 10/100 μM CCG-100602 vs. 44% by 10 μM CCG-1423) and similar efficacy against Rho/MKL1/SRF pathway-mediated transcription (by 78% with 100 μM CCG-100602 vs. 74% with 10 μM CCG-1423; IC50 = 9.8 μM/CCG-100602 vs. 1.5 μM/CCG-1423; by PC-3 SRE-luciferase assay), albeit at a reduced potency. CCG-100602 reduces the stiffening of spontaneously hypertensive rats (SHR) derived aortic VSMCs (1.12 μM) by inhibiting SRF/myocardin interaction and abrogates the increased aortic wall stiffness in SHR rats in vivo (7.5 mg/kg/d via s.c. osmotic pumps for 2 wks).

CCG-1423 analog with similar efficacy and much less cytotoxicity. Inhibits SRF/myocardin interaction and reduces aortic VSMCs stiffening in vitro and in vivo.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable